Omnicare Bankruptcy Plan Approved, Clearing Path for $250M Sale
CVS sits 32% above its 52-week low of $69.51 on light trading volume (0.3× avg).
Summary
A Texas bankruptcy judge approved Omnicare's wind-down plan, which pays all creditors in full and takes effect in October. This follows the $250M sale of Omnicare's operations to GenieRx Holdings and the $440M DOJ settlement over improper billing. The approval removes a major legal overhang for CVS, though the financial impact was already largely reflected in prior disclosures. The plan's effective date in October will finalize the divestiture and settlement.
At the time of this announcement, CVS was trading at $91.55 on NYSE in the Trade & Services sector, with a market capitalization of approximately $117.1B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.